Lucentis Related Published Studies
Well-designed clinical trials related to Lucentis (Ranibizumab)
Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. [2011.12]
Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. [2011.10]
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF COMBINATION RANIBIZUMAB (LUCENTIS) AND BROMFENAC (XIBROM) FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Study. [2011.08.20]
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. [2011.08]
A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. [2011.07]
Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. [2011.06]
Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. [2011.06]
Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. [2011.05]
Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. [2011.05]
Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. [2011.05]
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. [2011.04]
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. [2011.04]
Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. [2011.03]
ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol. [2011.01.17]
Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial. [2011.01]
A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. [2011]
A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice. [2011]
Incidence of retinal pigment epithelial tears after intravitreal ranibizumab
injection for neovascular age-related macular degeneration. [2011]
Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. [2010.11]
Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. [2010.11]
Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. [2010.11]
Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. [2010.10]
Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab. [2010.10]
A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. [2010.10]
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. [2010.09]
Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. [2010.09]
Bleb morphology and vascularity after trabeculectomy with intravitreal ranibizumab: a pilot study. [2010.09]
Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. [2010.09]
Phase I study of subconjunctival ranibizumab in patients with primary pterygium undergoing pterygium surgery. [2010.06]
Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. [2010.06]
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. [2010.06]
Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. [2010.05]
EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. [2010.05]
Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. [2010.04]
Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. [2010.04]
Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial. [2010.03]
Anatomical benefit from ranibizumab treatment of predominantly classic
neovascular age-related macular degeneration in the 2-year anchor study. [2010]
Dosing regimen and the frequency of macular hemorrhages in neovascular
age-related macular degeneration treated with ranibizumab. [2010]
Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular
age-related macular degeneration: PIER study year 2. [2010]
A randomised prospective double-masked exploratory study comparing combination
photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab
monotherapy in the treatment of neovascular age-related macular degeneration. [2010]
Ranibizumab for macular edema following central retinal vein occlusion: six-month
primary end point results of a phase III study. [2010]
Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. [2009.12]
Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. [2009.12]
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. [2009.11]
Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial. [2009.10.02]
A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. [2009.09]
Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. [2009.04]
Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. [2009.01]
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. [2009.01]
Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. [2008.10]
Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. [2007.10]
Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. [2007.02]
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. [2006.11]
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. [2006.10.05]
Ranibizumab for neovascular age-related macular degeneration. [2006.10.05]
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. [2006.10]
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. [2006.04]
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. [2006.04]
Well-designed clinical trials possibly related to Lucentis (Ranibizumab)
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. [2012]
Evaluation of masking study participants to intravitreal injections in a
randomized clinical trial. [2012]
Treatment of diabetic retinopathy with anti-VEGF drugs. [2011.05]
Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study. [2011.04]
Randomized trial of anesthetic methods for intravitreal injections. [2011.03]
Patient-reported outcomes among sham vs no-treatment controls from randomized trials. [2011.02]
Intravitreal injection anesthesia--comparison of different topical agents: a prospective randomized controlled trial. [2011.02]
An observational retrospective subgroup analysis of verteporfin photodynamic therapy-naive and previously treated patients in the focus trial. [2011.01]
Intravitreal injection anesthesia--comparison of different topical agents: a
prospective randomized controlled trial. [2011]
Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. [2010.12]
Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. [2010.10.06]
Vision-related function after low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. [2010.06]
Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. [2010.06]
Polypoidal choroidal vasculopathy: an angiographic discussion. [2010.03]
[Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations]. [2010]
Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort. [2009.09]
Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. [2009.08]
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. [2006.12]
Other research related to Lucentis (Ranibizumab)
Cerebrovascular accidents in patients treated for choroidal neovascularization
with ranibizumab in randomized controlled trials. [2012]
Factors associated with changes in visual acuity and central subfield thickness
at 1 year after treatment for diabetic macular edema with ranibizumab. [2012]
Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and
bevacizumab. [2012]
Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal
neovascularization. [2012]
Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the
management of neovascular age-related macular degeneration in patients with
persistent/recurrent macular fluid <30 days following treatment with intravitreal
anti-VEGF therapy (the LAST Study). [2012]
Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for
exudative age-related macular degeneration. [2012]
Intravitreal ranibizumab (lucentis) for the treatment of diabetic macular edema:
a systematic review and meta-analysis of randomized clinical control trials. [2012]
Ranibizumab and bevacizumab for treatment of neovascular age-related macular
degeneration: two-year results. [2012]
Long-term results of intravitreal ranibizumab, intravitreal ranibizumab with
photodynamic therapy, and intravitreal triamcinolone with photodynamic therapy
for the treatment of retinal angiomatous proliferation. [2012]
The effect of fellow eye visual acuity on visual acuity of study eyes receiving
ranibizumab for age-related macular degeneration. [2012]
EVEREST study: efficacy and safety of verteporfin photodynamic therapy in
combination with ranibizumab or alone versus ranibizumab monotherapy in patients
with symptomatic macular polypoidal choroidal vasculopathy. [2012]
Vandetanib: in medullary thyroid cancer. [2012]
Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. [2010.10.01]
Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. [2010.09.18]
Ranibizumab for Choroidal Neovascularization Secondary to Causes Other Than Age-Related Macular Degeneration: A Phase I Clinical Trial. [2010.07.31]
DOSING REGIMEN AND THE FREQUENCY OF MACULAR HEMORRHAGES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH RANIBIZUMAB. [2010.07.30]
Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system. [2010.07]
Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration. [2010.07]
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact. [2010.06.29]
A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. [2010.06.25]
Neovascular Age-related Macular Degeneration: Intraocular Cytokines and Growth Factors and the Influence of Therapy with Ranibizumab. [2009.10.06]
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. [2009.09]
Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. [2009.09]
Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. [2009.09]
A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration. [2009.08.21]
|
